Valeant Pharmaceuticals makes management change

In its US Dermatology and Gastrointestinal businesses

Valeant Pharmaceuticals has confirmed that Deb Jorn has resigned as Executive Vice President, Company Group Chairman. In this role, she was responsible for running the company's US Dermatology and Gastrointestinal businesses.

Eric Abramson, Vice President Dermatology & Immunology Marketing, has been appointed General Manager of the US Dermatology business and Dr Ari Kellen, Executive Vice President and Company Group Chairman will oversee Valeant's gastrointestinal business.

You may also like